Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | IKBKB | O14920 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 1.00 |
| ▸ | BCL2 | P10415 | 1/20 | 1.00 |
| ▸ | TXN | P10599 | 1/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 1.00 |
| ▸ | SPTSSB | Q8NFR3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gambogic Acid SCHEMBL12751296 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL13613351 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL13685812 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12025387 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12025441 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12045553 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL24089082 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12026374 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL16160279 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12045554 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013067543-A1 | METHODS AND COMPOSITIONS FOR ADMINISTERING A SPECIFIC WAVELENGTH PHOTOTHERAPY | FOLLEA INTERNATIONAL LTD. (CN) | 2013-05-10 | — | — | WO | claimed |
| US-20130115180-A1 | Methods And Compositions For Administering A Specific Wavelength Phototherapy | APPLIED BIOLOGY, INC. | 2013-05-09 | — | — | US | claimed |
| WO-2025064402-A1 | METHOD FOR TREATING SICKLE CELL DISEASE BY TARGETING SENESCENT CELLS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250041294-A1 | Synergistic compositions for use in the treatment of cancer | SARTAR THERAPEUTICS OY (FI) | 2025-02-06 | — | — | US | disclosed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | disclosed |
| US-20240316060-A1 | LASER AND BCL-2 INHIBITORS COMBINATION TO TREAT SOLID TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-09-26 | — | — | US | disclosed |
| CN-118354773-A | Synergistic composition for the treatment of cancer | 萨达治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117603669-B | Comprehensive blocking remover for oil, gas and water wells and use method thereof | 北京石大瑞伽石油技术开发有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117603669-A | Comprehensive blocking remover for oil, gas and water wells and use method thereof | 北京石大瑞伽石油技术开发有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-116602955-A | GPR108 inhibitor application | 上海中医药大学 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023105119-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | SARTAR THERAPEUTICS OY (FI) | 2023-06-15 | — | — | WO | disclosed |
| US-10111821-B2 | Methods and compositions for administering a specific wavelength phototherapy | APPLIED BIOLOGY, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| WO-2015103012-A1 | METHODS AND COMPOSITIONS FOR ADMINISTERING A SPECIFIC WAVELENGTH PHOTOTHERAPY | APPLIED BIOLOGY, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2014070266-A1 | COMPOSITIONS FOR ADMINISTERING A SPECIFIC WAVELENGTH PHOTOTHERAPY | GLOBAL LIFE SCIENCE PARTNERS LIMITED (CN) | 2014-05-08 | — | — | WO | disclosed |
| US-20140121732-A1 | METHODS AND COMPOSITIONS FOR ADMINISTERING A SPECIFIC WAVELENGTH PHOTOTHERAPY | APPLIED BIOLOGY, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20130310730-A1 | Methods And Compositions For Administering A Specific Wavelength Phototherapy | APPLIED BIOLOGY, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2013067543-A1 | METHODS AND COMPOSITIONS FOR ADMINISTERING A SPECIFIC WAVELENGTH PHOTOTHERAPY | FOLLEA INTERNATIONAL LTD. (CN) | 2013-05-10 | — | — | WO | disclosed |
| US-20130115180-A1 | Methods And Compositions For Administering A Specific Wavelength Phototherapy | APPLIED BIOLOGY, INC. | 2013-05-09 | — | — | US | disclosed |
| US-7592367-B2 | Compounds from Garcinia hanburyi, their use in treating cancer and method of separating epimers thereof | HONG KONG JOCKEY CLUB INSTITUTE OF CHINESE MEDICINE LTD. (CN) | 2009-09-22 | — | — | US | disclosed |
| US-20070149610-A1 | NOVEL COMPOUNDS FROM GARCINIA HANBURYI, THEIR USE IN TREATING CANCER AND METHOD OF SEPARATING EPIMERS THEREOF | HONG KONG JOCKEY CLUB INSTITUTE OF CHINESE MEDICINE LIMITED (CN) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149610-A1 | NOVEL COMPOUNDS FROM GARCINIA HANBURYI, THEIR USE IN TREATING CANCER AND METHOD OF SEPARATING EPIMERS THEREOF | CYP4A22, UGT2B17, ECI1 | TP53 4141/4885MAPT 4801/4885MAPK1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.